Results from a new study published in Clinical and Translational Immunology found that dual-target antibody therapy can enhance cancer-fighting T cells more effectively than current single-target ...
Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.
Holdings provides an update from the Company’s ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Irhythm Technologies (IRTC – Research Report), Vir ...
The market took a strong liking to the latest U.S. FDA guidance for Moleculin Biotech Inc.’s upcoming Miracle phase III trial testing annamycin in cancer. So much so that the company’s stock ...
The crucial drugs can have unintended consequences. Innovative therapies could shield the microbiome from their effects.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback